Enlivex Ltd. Ordinary Shares

ENLV XNAS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

71M

Short interest (Jul 15)

0.2%

Net Short (Jul 27 ): 0.0%

Borrow Fee

194.11%

↓ 15.2%

Available Shares

200K

↓ 50.9%

Price Chart

Company Overview

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Company Info

Exchange: NASDAQ

CIK: 0001596812

Asset Type: CS

Market Data

Market Cap: $70,694,463

Employees: 34

Status: Active

Short Interest

Current Borrow Fee 194.11%

Range: 184.56% - 194.11%

Available Shares 200K

Range: 50K - 150K

Recent Changes

Fee Change: ↑ 1.2%

Available Change: ↑ 51.5%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime